Decreased Expression of Nicotinamide Phosphoribosyltransferase in Patients with Juvenile Idiopathic Arthritis Receiving Methotrexate

REFERENCES

1. 1.↵
   1. Ye SQ,
   2. Simon BA,
   3. Maloney JP,
   4. Zambelli-Weiner A,
   5. Gao L,
   6. Grant A,
   7. et al.

   Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005;171:361–70.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Fukuhara A,
   2. Matsuda M,
   3. Nishizawa M,
   4. Segawa K,
   5. Tanaka M,
   6. Kishimoto K,
   7. et al.

   Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–30.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Revollo JR,
   2. Körner A,
   3. Mills KF,
   4. Satoh A,
   5. Wang T,
   6. Garten A,
   7. et al.

   Nampt/PFEB/visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363–75.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Luk T,
   2. Malam Z,
   3. Marshall JC

   . Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. J Leukoc Biol 2008;83:804–16.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Rongvaux A,
   2. Shea RJ,
   3. Mulks MH,
   4. Gigot D,
   5. Urbain J,
   6. Leo O,
   7. et al.

   Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002;32:3225–34.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Ozgen M,
   2. Suleyman SK,
   3. Aksoy K,
   4. Dagli N,
   5. Ustundag B,
   6. Isik A

   . Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol 2011;30:757–63.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Neumann E,
   2. Frommer KW,
   3. Vasile M,
   4. Müller-Ladner U

   . Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 2011;64:1159–69.

   OpenUrl
8. 8.↵
   1. Brentano F,
   2. Schorr O,
   3. Ospelt C,
   4. Stanczyk J,
   5. Gay RE,
   6. Gay S,
   7. et al.

   Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007;56:2829–39.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Moschen AR,
   2. Kaser A,
   3. Enrich B,
   4. Mosheimer B,
   5. Theurl M,
   6. Niederegger H,
   7. et al.

   Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748–58.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Busso N,
    2. Karababa M,
    3. Nobile M,
    4. Rolaz A,
    5. Van Gool F,
    6. Galli M,
    7. et al.

    Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008;3:e2267.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Beckers A,
    2. Organe S,
    3. Timmermans L,
    4. Vanderhoydonc F,
    5. Deboel L,
    6. Derua R,
    7. et al.

    Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther 2006;5:2211–17.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Fulco M,
    2. Cen Y,
    3. Zhao P,
    4. Hoffman EP,
    5. McBurney MW,
    6. Sauve AA,
    7. et al.

    Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008;14:661–73.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Katerelos M,
    2. Mudge SJ,
    3. Stapleton D,
    4. Auwardt RB,
    5. Fraser SA,
    6. Chen CG,
    7. et al.

    5-aminoimidazole-4-carboxamide ribonucleoside and AMP-activated protein kinase inhibit signaling through NF-κB. Immunol Cell Biol 2010;88:754–60.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Peiro C,
    2. Romacho T,
    3. Sánchez-Ferrer CF

    . Clinical implications of visfatin/PBEF/Nampt for development of vascular inflammation and atherosclerosis. JCMD 2011;2:34–8.

    OpenUrl